Stock Evaluator: Xvivo Perfusion AB (publ) (XVIPY)

Xvivo Perfusion AB (publ) XVIPY

$6.88 0.00 0.00%
September 2, 2026 10:46:55 AM EST November 10, 2021 Volume: 0
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Health Care Equipment & Supplies

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden. It operates through Thoracic; Abdominal; Services; and other segments. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidneys with oxygenated solution for up to 24 hours; Liver Assist that provides clinicians a choice of perfusion protocols whether hypothermic, normothermic, sub-normothermic, or a combination; XVIVO System (XPS), a comprehensive ex vivo lung perfusion (EVLP) platform that offers an overview of the entire process; and STEEN Solution, a buffered extracellular solution intended for the assessment of isolated lungs after removal from the donor in preparation for eventual transplantation into a recipient. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XPS Disposable Lung Kit that contains all the necessary devices and tubing to run a normothermic EVLP procedure on the XPS; XVIVO Organ Chamber, a sterile single-use container intended to be used as a temporary receptacle for isolated donor lungs; and XVIVO Lung Cannula Set, a sterile single-use set that connects isolated donor lungs to an extracorporeal perfusion system for ex-vivo assessment. In addition, the company offers Kidney Assist that provides clinicians with a choice of perfusion protocols from hypothermic to normothermic perfusion; and Gisto, an integrated system for organ transportation. It operates in Sweden; The Netherlands; The United States; Italy; North and South America; Asia/Pacific and Oceania; and internationally. Xvivo Perfusion AB (publ) was incorporated in 1998 and is headquartered in Mölndal, Sweden.

Financial Summary

Share Statistics XVIPY Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $866.2 $423.7 43%
Shares Out (Mil) 3.3 41.5 11%
Institutional Ownership 49.6% 83.6% 24%
Float (Mil) 25.1 35.5 33%
Beta 1.46 0.88 81%
Avg Daily Volume (000s) 1 336 4%
Price Change
(52-week)
na 65.2% na
Growth XVIPY Industry
Median
Percentile
(All Stocks)
Sales (5yr) 32.1% 11.8% 91%
Net Income (5yr) 20.2% (5.8%) 73%
EPS (5yr) 19.6% 10.4% 67
Dividends (5yr) 0.0% 0.0% 0%
Cash Flow (5yr) (20.6%) (15.5%) 32%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates na na na
Current EPS na na na
Month Ago EPS na na na
# Rev Up na na na
# Rev Down na na na
Three Months Ago EPS na na na
Year/Year Chg na na na
Financials XVIPY Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) $92 $119 25%
Net Income (TTM) (Mil) $9 ($9) 45%
EPS (TTM) $0.290 ($0.400) 49%
Operating Cash Flow (TTM) (Mil) $24 ($3) 42%
Net Cash Flow (TTM) (Mil) ($2) $1 38%
Long-Term Debt (Q1) (Mil) $11 $23 29%
Enterprise Value (Q1) (Mil) $757 $376 38%
Valuation XVIPY Industry
Median
Percentile
(All Stocks)
P/B na 2.87 na
P/E na 27.8 na
Dividend Yield na 0.0% na
PEG (5yr hist) na 1.6 na
Ratios XVIPY Industry
Median
Percentile
(All Stocks)
Gross Margin 72.3% 58.5% 83%
Net Margin 9.9% (6.9%) 62%
ROA 3.6% (13.3%) 65%
ROE 4.1% (13.3%) 42%
Liabilities to Assets 12.9% 46.2% 8%
F-Score na 4 na

Xvivo Perfusion AB (publ) did not pass any screens on 9/3/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors